![]() Rizza L et al (2010) Evaluation of the effect of topical agents on radiation-induced skin disease by reflectance spectrophotometry. įisher J et al (2000) Randomized phase III study comparing Best Supportive Care to Biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation: Radiation Therapy Oncology Group (RTOG) 97–13. Įlliott EA et al (2006) Phase III Trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99–13. (96)00019-4Ībbas H, Bensadoun RJ (2012) Trolamine emulsion for the prevention of radiation dermatitis in patients with squamous cell carcinoma of the head and neck. Hadorn DC et al (1996) Rating the quality of evidence for clinical practice guidelines. ![]() Guyatt GH et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Wong RK et al (2013) Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. ![]() īolognia J, Jorizzo JL, Schaffer JV (2012) Dermatology, 3rd edn. Hegedus F, Mathew LM, Schwartz RA (2017) Radiation dermatitis: an overview. Rzepecki A et al (2022) Characterizing the effects of radiation dermatitis on quality of life: a prospective survey-based study. Huang CJ et al (2015) RTOG, CTCAE and WHO criteria for acute radiation dermatitis correlate with cutaneous blood flow measurements. įerreira EB et al (2017) Topical interventions to prevent acute radiation dermatitis in head and neck cancer patients: a systematic review. Rosenthal A, Israilevich R, Moy R (2019) Management of acute radiation dermatitis: a review of the literature and proposal for treatment algorithm. Xie Y et al (2021) Risk factors related to acute radiation dermatitis in breast cancer patients after radiotherapy: a systematic review and meta-analysis. The use of trolamine and hyaluronic acid does not significantly affect the incidence of RD. The results of this systematic review and meta-analysis indicate that Biafine® can prevent grade 3 + RD in breast cancer patients. The remaining agents (trolamine alone and hyaluronic acid/hyaluronan) did not significantly prevent the occurrence of RD. Among the topical non-steroidal agents analyzed, only the use of Biafine® in breast cancer patients was significant in preventing grade 4 and 3 + RD as classified by the Radiation Therapy Oncology group (RTOG) scale (OR = 0.07, 95% CI 0.01–0.63, p = 0.02, and OR 0.11, 95% CI 0.03–0.41, p < 0.01, respectively). ResultsĪ total of six RCTs were included, comprising 627 patients. PubMed, Embase and Cochrane databases (1946 to December 2022) were searched using PRISMA guidelines to identify randomized controlled trials (RCTs) that investigated the use of topical non-steroidal agents in the prevention of RD in patients undergoing radiotherapy. Currently, no consensus exists regarding the prevention of RD. ![]() Biafine does not contain any sunscreen, because it is applied after prolonged sun exposure.Radiation dermatitis (RD) is a common side effect of radiation therapy, affecting a majority of breast and head and neck cancer patients with a negative impact on quality of life. All wounds, burns and irritations should be cleaned before application and bandaging. Biafine has been studied in clinical trials for use after plastic and cosmetic surgery.īiafine is for topical use only and should not be used on bleeding wounds and skin rashes (especially those caused by an allergic reaction). Initial application may produce a slight tingling sensation from the penetrating properties of the formulation. While Biafine is an emulsion, it is non-comedogenic because it stimulates tissue debridement, hydration and regeneration. Biafine hydrates skin tissue, adding water to healing tissue, softening scars, promoting the body's antibacterial activity and reducing contamination. Biafine contains clinically tested ingredients in an herbal base and its use includes burn dressings, post-treatment for cosmetic and plastic surgery and dermatology treatments (such as sunburn).īiafine is manufactured by Laboratoire Medix in France as a topical treatment for wounds and burns. Food and Drug Administration approval in 2006, and these benefits underscore the heritage of the product's use in France for over 25 years. The clinical benefits of Biafine to stimulate all phases of wound healing have been studied in the United States prior to U.S. Westman Atelier Le Box - The Petal EditionĪugustinus Bader The Icons with The Rich Creamīiafine cream emulsion, a cult French pharmacy favorite, is a topical non-steroidal cream for treating burns, wounds and irritations.
0 Comments
Leave a Reply. |